Related content

Efficacy, Tolerability and Cost Effectiveness of Disease-Modifying Antirheumatic Drugs and Biologic Agents in Rheumatoid Arthritis

By Nurmohamed Michael T.   Dijkmans Ben A.C.  

Drugs, Vol. 65, Iss. 5, 2005-01 ,pp. : 661-694

Adis International

Access to resources Recommend Favorite

Guidelines for the Use of Conventional and Newer Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis

By Díaz-Borjón Alejandro  

Drugs & Aging, Vol. 26, Iss. 4, 2009-05 ,pp. : 273-293

Adis International

Access to resources Recommend Favorite

The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs

By Drozdzik Marek   Rudas Tomasz   Pawlik Andrzej   Kurzawski Mateusz   Czerny Bogusław   Gornik Wanda   Herczynska Magdalena  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 11, 2006-11 ,pp. : 933-937

Springer Publishing Company

Access to resources Recommend Favorite

Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis

By Fleischmann Roy  

Expert Opinion on Drug Safety, Vol. 2, Iss. 4, 2003-07 ,pp. : 347-365

Informa Healthcare

Access to resources Recommend Favorite

A Clinical and Economic Review of Disease-Modifying Antirheumatic Drugs

By Gabriel S.E.  

PharmacoEconomics, Vol. 19, Iss. 7, 2001-07 ,pp. : 715-728

Adis International

Access to resources Recommend Favorite